Helsinn Group, of Lugano, Switzerland, and Chugai Pharma Marketing Ltd., a wholly owned subsidiary of Chugai Pharmaceutical Co. Ltd., of Tokyo, said they inked an agreement for the marketing rights of netupitant-palonosetron fixed-dose combination (NEPA), being evaluated for the prevention of chemotherapy-induced nausea and vomiting.